#USA #Parsippany, NJ #Dexcel Pharma #Zubsolv #Orexo AB

Dexcel Pharma USA Expands Portfolio with Zubsolv® Acquisition

In a noteworthy development for the pharmaceutical industry, Dexcel Pharma USA has officially closed an Asset Purchase Agreement with Orexo AB, securing the U.S. rights to Zubsolv® (buprenorphine and naloxone) sublingual tablets. This acquisition is not just a tactical move for the company, but a fundamental milestone that will enhance their capabilities in promoting branded products across the United States.

Dexcel Pharma's CEO, Doug Boothe, expressed enthusiasm regarding the addition of Zubsolv® to their product lineup, stating that it will significantly bolster the company’s expanding operations in the U.S. market. With Zubsolv°, a medication aimed at treating opioid use disorder, Dexcel aims to leverage its established sales and marketing platform to drive strategic growth early on in 2026.

The acquisition of Zubsolv® is part of a broader strategy by Dexcel to establish a strong presence within the competitive pharmaceutical sector in the United States. Having previously focused on bringing a range of generic and branded drugs to market, this acquisition indicates Dexcel’s commitment to addressing pressing healthcare needs, particularly within the realm of addiction treatment.

Zubsolv® has been recognized for its effectiveness in managing opioid addiction and offers an important option for healthcare providers treating patients struggling with this condition. With the ongoing opioid crisis in the U.S., the addition of Zubsolv® to their portfolio is expected to provide critical support in expanding access to effective treatment options.

Boothe also acknowledged the hard work of Dexcel Pharma's employees and their advisory partners, including legal experts DLA Piper LLP (US), who played vital roles in facilitating this transaction. Their collaborative efforts reflect Dexcel Pharma’s commitment to professional standards and robust business strategies, ensuring a seamless acquisition process.

Looking forward, Dexcel Pharma anticipates working closely with both new and existing customers and partners. The company emphasizes its dedication to ensuring continuous access to this essential therapy amid the growing demand for treatment methods tailored to address opioid use disorders.

For more information about Dexcel Pharma, you can explore their website at www.dexcelpharmausa.com. This acquisition not only signifies Dexcel Pharma USA's ambition to expand its market share in the U.S. but also highlights the critical role pharmaceutical companies must play in addressing urgent public health issues. As they embark on this new chapter, Dexcel is poised to enhance its service to patients and healthcare professionals alike, reaffirming its status as a key player in the industry.

Dexcel Pharma USA, with its roots as the largest private pharmaceutical company in Israel, has continuously evolved by commercializing a wide array of drugs. Our state-of-the-art research and development facilities reflect Dexcel's commitment to high-quality pharmaceutical products, ensuring that they can meet the changing needs of healthcare while fostering long-term partnerships across the drug development pipeline.

Conclusion

This acquisition of U.S. rights to Zubsolv® is a testament to Dexcel Pharma USA’s strategic vision and mission. By evolving their product offerings, they are not only addressing marketplace demands but are also contributing to the critical field of addiction treatment. As this pharmaceutical giant continues to grow its operations and adapt to market changes, many will be watching to see how Dexcel impacts the landscape of addiction therapy and mental health treatment in the U.S.